Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service pacemaker, ICD & CRT implantation cases in Iowa: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (249 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 36 | 1,834 | 24% |
| 2020 | 34 | 1,628 | 27% |
| 2021 | 36 |
Pacemaker, leadless, ICD, S-ICD, CRT, and generator replacements. Professional codes (what the surgeon bills): CPT 33206, 33207, 33208, 33274, 33249, 33270, 33262, 33263, 33264; the hospital bills MS-DRG 242, 243, 244, 226, 227, 275, 276, 277.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 49% of the cases CMS names in Iowa; 21 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| EP ablation | 27 | 1,505+14%/yr | +14%/yr | 3.00.9× | 0% | 2,760 in 2030+11%/yr |
| LAA occlusion & loop recorders |
Pacemaker, ICD & CRT implantation in every state, and its device makers · Every procedure market in Iowa · Every state · Compare with Illinois
| 2024 |
| 1,666 |
| 40% |
| 2025 est. | ≈ 1,620 | – |
| 2026 est. | ≈ 1,660 | – |
| 1,918 |
| 30% |
| 2022 | 33 | 1,633 | 34% |
| 2023 | 33 | 1,805 | 38% |
| 2024 | 34 | 1,666 | 40% |
| 2025 from claims | – | 1,618 1,484–1,711 | 41% |
| 2026 forecast | – | 1,663 1,463–1,919 | 40% |
| 2027 forecast | – | 1,675 1,432–1,996 | 40% |
| 2028 forecast | – | 1,687 1,408–2,066 | 41% |
| 2029 forecast | – | 1,700 1,388–2,132 | 41% |
| 2030 forecast | – | 1,712 1,372–2,194 | 42% |
In 2025, 37% inpatient hospital, 63% hospital outpatient.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient |
|---|---|---|
| 2026 · ~1,700 | ~620 | ~1,000 |
| 2027 · ~1,700 | ~630 | ~1,000 |
| 2028 · ~1,700 | ~640 | ~1,000 |
The forecast’s cases at the projected mix.
The mix is steady: the trend moves no setting by a point or more by 2028.
| −4.9%/yr |
| 5.0 |
| 0% |
| 5,520 in 2030+0.5%/yr |
| Michigan | 80 | 4,354−7%/yr | −7%/yr | 5.4 | 1% | 3,930 in 2030−1.7%/yr |
| Indiana | 79 | 4,130−1.9%/yr | −1.9%/yr | 6.1 | 0% | 4,280 in 2030+0.6%/yr |
| Missouri | 69 | 3,704−3.1%/yr | −3.1%/yr | 6.2 | 1% | 3,900 in 2030+0.9%/yr |
| Minnesota | 54 | 2,678−1.9%/yr | −1.9%/yr | 6.2 | 2% | 3,620 in 2030+5.2%/yr |
| Wisconsin | 51 | 2,533−2.6%/yr | −2.6%/yr | 4.7 | 0% | 2,880 in 2030+2.1%/yr |
| Kansas | 48 | 2,322−5%/yr | −5%/yr | 5.9 | 13% | 2,470 in 2030+1%/yr |
| Nebraska | 20 | 1,389−4%/yr | −4%/yr | 5.5 | 4% | 1,420 in 2030+0.4%/yr |
| South Dakota | 8 | 587−1.6%/yr | −1.6%/yr | 4.7 | 0% | 750 in 2030+4.1%/yr |
| North Dakota | 10 | 559−1.6%/yr | −1.6%/yr | 5.8 | 0% | 640 in 2030+2.2%/yr |
| 21 |
| 859+11%/yr |
| +11%/yr |
| 1.80.6× |
| 5% |
| 1,760 in 2030+13%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Boston Scientific leads with 47% of company spending on these surgeons in 2025, +14 pts on 2024.
In 2025, 7 companies reported engagement with Iowa’s surgeons worth $83K in consulting, speaking, meals and travel tied to these products, about $2,455 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 339 clearances and approvals in the category, 3 recalled product lines (2 Class I). A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.